Johnson & Johnson (JNJ) Given Daily Media Impact Score of 1.56
News articles about Johnson & Johnson (NYSE:JNJ) have trended somewhat positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Johnson & Johnson earned a media sentiment score of 1.56 on their scale. InfoTrie also gave headlines about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Johnson & Johnson’s score:
- Janssen (JNJ) Announces New Phase 3 CASSINI Data Presented on Use of XARELTO for VTE Prevention in High-Risk Cancer Patients (streetinsider.com)
- Johnson & Johnson: An Excellent Business Selling at a Rational Price (gurufocus.com)
- Johnson & Johnson (JNJ) Expected to Announce Earnings of $1.95 Per Share (americanbankingnews.com)
- Better Buy: Intuitive Surgical vs. Johnson & Johnson (msn.com)
- Johnson & Johnson’s Xarelto fails to beat placebo in late-stage study in high-risk cancer patients (seekingalpha.com)
Johnson & Johnson stock opened at $146.03 on Thursday. The stock has a market capitalization of $394.12 billion, a price-to-earnings ratio of 20.00, a P/E/G ratio of 2.29 and a beta of 0.59. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.47%. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.
A number of equities analysts recently commented on JNJ shares. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Citigroup lifted their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Raymond James lifted their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research note on Friday, September 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $143.90.
In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $145.96, for a total value of $38,601,311.40. Following the completion of the sale, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 351,748 shares of company stock valued at $51,092,647. 0.22% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-given-daily-media-impact-score-of-1-56/2663328.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Why is the LIBOR significant?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.